Exosomes as an Emerging Plasmid Delivery Vehicle for Gene Therapy
Pharmaceutics · 27.06.2023 · 15 (7) · 1832
DOI: 10.3390/pharmaceutics15071832 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 27.06.2023. Verfasst von Margaret Wallen und 3 weiteren Autor:innen. Beteiligte Einrichtung: 3P Biotechnologies, Inc., Louisville, KY 40202, USA. Die Arbeit wurde bisher 36-mal zitiert (Crossref) und nennt 167 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, USPHS, Agnes Brown Duggan Endowment.
Abstract (Originalsprache)
Despite its introduction more than three decades ago, gene therapy has fallen short of its expected potential for the treatment of a broad spectrum of diseases and continues to lack widespread clinical use. The fundamental limitation in clinical translatability of this therapeutic modality has always been an effective delivery system that circumvents degradation of the therapeutic nucleic acids, ensuring they reach the intended disease target. Plasmid DNA (pDNA) for the purpose of introducing exogenous genes presents an additional challenge due to its size and potential immunogenicity. Current pDNA methods include naked pDNA accompanied by electroporation or ultrasound, liposomes, other nanoparticles, and cell-penetrating peptides, to name a few. While the topic of numerous reviews, each of these methods has its own unique set of limitations, side effects, and efficacy concerns. In this review, we highlight emerging uses of exosomes for the delivery of pDNA for gene therapy. We specifically focus on bovine milk and colostrum-derived exosomes as a nano-delivery “platform”. Milk/colostrum represents an abundant, scalable, and cost-effective natural source of exosomes that can be loaded with nucleic acids for targeted delivery to a variety of tissue types in the body. These nanoparticles can be functionalized and loaded with pDNA for the exogenous expression of genes to target a wide variety of disease phenotypes, overcoming many of the limitations of current gene therapy delivery techniques.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- 3P Biotechnologies, Inc., Louisville, KY 40202, USA.
- Brown Cancer Center, University of Louisville, Louisville, KY 40202, USA.
- Department of Medicine, University of Louisville, Louisville, KY 40202, USA.
- Department of Pharmacology and Toxicology, University of Louisville, Louisville, KY 40202, USA.
ORCID-Profile: Farrukh Aqil
Förderung
- NIH HHS
- USPHS
- Agnes Brown Duggan Endowment
Zitieren
APA
Wallen, M., Aqil, F., Spencer, W., & Gupta, R. C. (2023). Exosomes as an Emerging Plasmid Delivery Vehicle for Gene Therapy. Pharmaceutics, 15(7), 1832. https://doi.org/10.3390/pharmaceutics15071832
Vancouver
Wallen M, Aqil F, Spencer W, Gupta RC. Exosomes as an Emerging Plasmid Delivery Vehicle for Gene Therapy. Pharmaceutics. 2023;15(7):1832. doi:10.3390/pharmaceutics15071832
BibTeX
@article{Wallen2023,
author = {Wallen, Margaret and Aqil, Farrukh and Spencer, Wendy and Gupta, Ramesh C},
title = {Exosomes as an Emerging Plasmid Delivery Vehicle for Gene Therapy},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {7},
pages = {1832},
doi = {10.3390/pharmaceutics15071832}
}
EUVIMED